A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) - COPD

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2061250099

Enrollment

1156

Registered

2026-03-13

Start date

2026-04-15

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Phase 2 Treatment Arm A: PF-07275315 dose 1 -SC injection Phase 2 Treatment Arm B: PF-07275315-dose 2 -SC injection Phase 2 Treatment Arm C: Placebo -SC injection matched Phase 3 Treatment Arm A: PF-0

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: *Diagnosis of chronic obstructive pulmonary disease (COPD) for at least 12 months (based on Global Initiative for Chronic Obstructive Lung Disease [GOLD] definition). *Spirometry values (post-bronchodilator forced expiratory volume in 1 second [FEV1]/forced vital capacity [FVC] less than [= 6 months prior to Screening Visit 1 and at a stable dose for >=3 months *Documented history of at least 2 moderate or severe ECOPD within the last 12 months prior to Screening.

Exclusion criteria

Exclusion criteria: *Significant pulmonary disease other than COPD. *Requirement for continuous chronic treatment with oxygen at >4.0 liters / minute by nasal cannula or equivalent. *Hypoxemia with a resting SpO2 <88% while breathing ambient air (or on the participant's usual level of oxygen supplementation). *Clinically significant cardiovascular disease, acute and/or severe left heart failure, or heart failure partial ejection fraction, and/or cor pulmonale.

Design outcomes

Primary

Measure	Time frame
Phase 2 part: Change from baseline in pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 24 Phase 3 part: Annualized rate of moderate or severe ECOPD	—

Secondary

Measure	Time frame
Phase 2 part: Annualized rate of moderate or severe ECOPD Change from baseline in pre-BD FEV1 up to Week 24 Change from baseline in trough, pre- and post-BD FEV1 up to Week 24 Change from baseline in trough, pre- and post-BD FVC and FEV1/FVC ratio, % predicted FEV1, % predicted FVC up to Week 24 Change from baseline in trough FEV1 responsiveness to BD up to Week 24 Incidence and severity of TEAEs throughout Phase 2 part of the study Incidence of treatment-emergent adverse events and serious adverse events leading to discontinuation Incidence of clinical abnormalities in clinical laboratory values, ECG measurements, and vital signs Change from baseline in clinical laboratory values, ECG measurements, and vital signs Phase 3 part: Change from baseline in pre- and post-BD FEV1 at Week 12 and Week 52 Percentage of participants with >=4 points improvement from baseline in Saint George's Respiratory Questionnaire (SGRQ) score at Week 52 Percentage of participants with >=2 points improvement from baseline in the COPD Assessment Test (CAT) total score at Week 52 Percentage of participants with >=2 points improvement from baseline in E-RS:COPD total score at Week 52 Annualized rate of severe ECOPD *Annualized rate of exacerbations requiring emergency department visit and/or hospitalization	—

Measure

Time frame

Phase 2 part: *Annualized rate of moderate or severe ECOPD *Change from baseline in pre-BD FEV1 up to Week 24 *Change from baseline in trough, pre- and post-BD FEV1 up to Week 24 *Change from baseline in trough, pre- and post-BD FVC and FEV1/FVC ratio, % predicted FEV1, % predicted FVC up to Week 24 *Change from baseline in trough FEV1 responsiveness to BD up to Week 24 *Incidence and severity of TEAEs throughout Phase 2 part of the study *Incidence of treatment-emergent adverse events and serious adverse events leading to discontinuation *Incidence of clinical abnormalities in clinical laboratory values, ECG measurements, and vital signs *Change from baseline in clinical laboratory values, ECG measurements, and vital signs Phase 3 part: *Change from baseline in pre- and post-BD FEV1 at Week 12 and Week 52 *Percentage of participants with >=4 points improvement from baseline in Saint George's Respiratory Questionnaire (SGRQ) score at Week 52 *Percentage of participants with >=2 points improvement from baseline in the COPD Assessment Test (CAT) total score at Week 52 *Percentage of participants with >=2 points improvement from baseline in E-RS:COPD total score at Week 52 *Annualized rate of severe ECOPD *Annualized rate of exacerbations requiring emergency department visit and/or hospitalization

—

Countries

Canada, China, India, Japan, South Korea, Taiwan, United States

Contacts

Public ContactClinical Trials Information Desk

Pfizer R&D Japan G.K.

clinical-trials@pfizer.com+81-3-5309-7000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026